

TABLE 9B.—HOSPITAL RECLASSIFICATIONS AND REDESIGNATIONS BY INDIVIDUAL HOSPITAL UNDER SECTION 508 OF PUBLIC LAW 108–173—FY 2011—Continued

CCN	Note	Geographic CBSA	Wage index CBSA section 508 reclassification	Own wage index
330106		35004		1.4341
330126		35644	1.2867	
330135		35644	1.2867	
330205		35644	1.2867	
330264		35004	1.2529	
340002		16740	0.9087	
390001		10900	0.9370	
390003		10900	0.9370	
390045	**	10900	0.9370	
390072		10900	0.9370	
390095		10900	0.9370	
390119		10900	0.9370	
390137		10900	0.9370	
390169		10900	0.9370	
390185		29540	0.9852	
390192		10900	0.9370	
390237		10900	0.9370	
390270		29540	0.9852	
430005		39660	1.0934	
470003		14484	1.1629	
490001		31340	0.8514	
530015		53		1.0577

* These hospitals are assigned a wage index value under a special exceptions policy (see FY 2005 IPPS final rule, 69 FR 49105).

** This hospital has been assigned a wage index under a special exceptions policy (see FY 2007 IPPS final rule, 71 FR 48070).

[FR Doc. 2011–8209 Filed 4–6–11; 8:45 am]

BILLING CODE 4120–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2011–N–0002]

The 14th Annual Food and Drug Administration-Orange County Regulatory Affairs Educational Conference in Irvine, California: New Regulatory Challenges

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of conference.

The Food and Drug Administration (FDA) is announcing the following conference: 14th Annual Educational Conference co-sponsored with the Orange County Regulatory Affairs Discussion Group (OCRA). The conference is intended to provide the drug, device, biologics, and dietary supplement industries with an opportunity to interact with FDA reviewers and compliance officers from the centers and District Offices, as well as from other industry experts. The main focus of this interactive conference will be product approval, compliance, and risk management in the three medical product areas. Industry speakers, interactive Q & A, and

workshop sessions will also be included to assure open exchange and dialogue on the relevant regulatory issues.

Date and Time: The conference will be held on June 8 and 9, 2011, from 7:30 a.m. to 5 p.m.

Location: The conference will be held at the Irvine Marriott Hotel, 18000 Von Karman Ave., Irvine, CA 92612.

Contact: Linda Hartley, Office of Regulatory Affairs, Food and Drug Administration, 19701 Fairchild, Irvine, CA 92612, *Voice:* 949–608–4413, *Fax:* 949–608–4417; or Orange County Regulatory Affairs Discussion Group, Attention to Detail, 5319 University Dr., suite 641, Irvine, CA 92612, *Voice:* 949–387–9046, *Fax:* 949–387–9047, *Web site:* <http://www.ocra-dg.org>. (FDA has verified the Web site address, but FDA is not responsible for any subsequent changes to the Web site after this document publishes in the **Federal Register**.)

Registration and Meeting Information: See OCRA's Web site at <http://www.ocra-dg.org>. Contact Attention to Detail at 949–387–9046.

Before May 1, 2011, registrations fees are as follows: \$675.00 for members, \$725.00 for non-members and \$475.00 for FDA/Government/Students.* After May 1, 2011, \$725.00 for members, \$775.00 for non-members, and \$475.00 for FDA/Government/Students.*

* OCRA student rate applies to those individuals enrolled in a regulatory or

quality-related academic program at an accredited institution. Proof of enrollment required.

The registration fee will cover actual expenses including refreshments, lunch, materials, parking, and speaker expenses.

If you need special accommodations due to a disability, please contact Linda Hartley (*see Contact*) at least 10 days in advance.

Transcripts: Transcripts will not be available for the conference.

Dated: April 1, 2011.

Leslie Kux,

Acting Assistant Commissioner for Policy.

[FR Doc. 2011–8283 Filed 4–6–11; 8:45 am]

BILLING CODE 4160–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2010–N–0443]

Cathryn Lyn Chatman (also known as Cathryn Lyn Garcia): Debarment Order

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is issuing an order under the Federal Food, Drug, and Cosmetic Act (the FD&C Act) debarring